openPR Logo
Press release

Non-small Cell Lung Cancer (NSCLC) Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

05-06-2024 07:10 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Non-small Cell Lung Cancer (NSCLC) Pipeline

Non-small Cell Lung Cancer (NSCLC) Pipeline

Non-small Cell Lung Cancer (NSCLC) pipeline constitutes 135+ key companies continuously working towards developing 150+ NSCLC treatment therapies, analyses DelveInsight

DelveInsight's 'Non-small Cell Lung Cancer Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Non-small cell lung cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Non-small cell lung cancer pipeline domain.

To know more about the NSCLC Pipeline report offerings, click here: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Non-small Cell Lung Cancer Pipeline Report
• Over 150+ Non-small cell lung cancer pipeline therapies are in various stages of development, and their anticipated acceptance in the Non-small cell lung cancer market would significantly increase market revenue.
• Some of the Non-small cell lung cancer companies developing novel drug candidates to improve the NSCLC treatment landscape include BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Abbvie, Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Innovent Biologics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others.
• Promising Non-small cell lung cancer therapies in various stages of development include INBRX-106, Datopotamab deruxtecan, Bintrafusp alfa, Patritumab deruxtecan, GB 1211, BBP 398, Cofetuzumab pelidotin, Abemaciclib, BNT 116, JMT101, RMC-4630, MGY 825, Adagrasib, JDQ443, TGRX 326, CKD 702, Citarinostat, IBI 110, XZP 3621, BAY 2927088, SRF388, ABBV 514, Gentuximab injection, Befotertinib, Geptanolimab, Naporafenib, IMU-201, Binimetinib, HS 10241, APX005M, Finotonlimab, Encorafenib, Autologous tumour infiltrating lymphocytes, and others.
• In Oct 2022, eftilagimod alpha has been given a fast-track designation by the FDA for use as the first-line treatment for patients with stage IIIB/IV non-small cell lung cancer when combined with pembrolizumab.
• In Oct 2022, BerGenBio announced that they had begun the phase Ib/IIa trial evaluating bemcentinib in first-line non-small cell lung cancer patients with STK11 mutations.
• In May 2022, BridgeBio Pharma and Bristol Myers Squibb (BMS) entered an exclusive license agreement for developing and marketing BBP-398 in oncology. An inhibitor of SHP2, BBP-398, was created through a partnership with the Therapeutics Discovery division of The University of Texas MD Anderson Cancer Center, US. Under the deal, BMS will make upfront and milestone payments of up to $905m to BridgeBio.

Request a sample and discover the recent breakthroughs happening NSCLC pipeline landscape in @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Non-small Cell Lung Cancer Overview
About 85% of all cases of lung cancer are non-small-cell lung cancer (NSCLC), which includes all epithelial lung cancers besides small-cell lung cancer (SCLC). NSCLC tumors come in three different varieties: a) Adenocarcinoma begins in cells that produce mucus and other substances inside air sacs, frequently in the outer regions of your lungs. It is the most prevalent form of lung cancer in people under 45 who smoke, nonsmokers, and both.
The common NSCLC symptoms include chest pain, wheezing, weight loss, shortness of breath, coughing up blood, and others. Several imaging tests such as X-ray, MRI, PET Scans, CT Scans, and others are used for NSCLC diagnosis. Apart from imaging tests, other tests used for NSCLC diagnosis include sputum cytology, bronchoscopy, and mediastinoscopy.

Non-small Cell Lung Cancer Pipeline Analysis: Drug Profile
Datopotamab deruxtecan: Daiichi Sankyo
Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Datopotamab deruxtecan is one of three leading ADCs in Daiichi Sankyo's oncology pipeline and one of the most advanced programs in AstraZeneca's ADC scientific platform. Datopotamab deruxtecan is made up of a humanized anti-TROP2 IgG13 monoclonal antibody developed in collaboration with Sapporo Medical University, which is linked to several topoisomerases I inhibitor payloads, an exatecan derivative via tetrapeptide-based cleavable linkers.
MRTX849: Mirati Therapeutics
Adagrasib (MRTX849) is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized for long-term target inhibition, which may be important in treating KRASG12C-mutated cancers because the KRASG12C protein regenerates every 24-48 hours. Adagrasib is being tested in patients with advanced KRASG12C-mutated solid tumors, such as NSCLC, colorectal cancer, and pancreatic cancer, as a monotherapy and in combination with other anti-cancer therapies.

Non-small Cell Lung Cancer Therapies and Key Companies
• Datopotamab deruxtecan: Daiichi Sankyo
• JDQ443: Novartis
• MRTX849: Mirati Therapeutics
• INBRX-106: Inhibrx
• GB 1211: Galecto Biotech
• BBP 398: BridgeBio Pharma
• TGRX 326: Shenzhen TargetRx
• SRF388: Surface Oncology
• ABBV 514: AbbVie

Learn more about the NSCLC emerging pipeline therapies and Non-small Cell Lung Cancer Clinical Trials: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Non-small Cell Lung Cancer Pipeline Therapeutics Assessment
By Product Type
o Monotherapy
o Combination Therapy
By Stage
o Discovery
o Pre-Clinical
o Phase I
o Phase II
o Phase III
o Pre-registration
By Route of Administration
o Intranasal
o Intrathecal
o Intravenous
o Oral
o Parenteral
o Intramuscular
o Transdermal
By Molecule Type
o Antisense oligonucleotide
o Gene therapy
o Hormones
o Neuropeptides
o Oligonucleotides
o Small Molecule
o Triglyceride

Scope of the Non-small Cell Lung Cancer Pipeline Report
• Coverage: Global
• Key Non-small Cell Lung Cancer Companies: BridgeBio Pharma (NASDAQ: BBIO), Daiichi Sankyo, EMD Serono (ETR: MRK), Merck (NYSE: MRK), Abbvie (NYSE: ABBV), Pfizer (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), BioNTech SE (NASDAQ: BNTX), Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer (ETR: BAYN), GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene (ASX: IMU), Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb (NYSE: BMY), Surface Oncology (NASDAQ: SURF), Inhibrx (NASDAQ: INBX), Sinocelltech, Mirati Therapeutics (NASDAQ: MRTX), REVOLUTION Medicines (NASDAQ: RVMD), Yong Shun Technology Development, Iovance Biotherapeutics (NASDAQ: IOVA), Galecto Biotech (NASDAQ: GLTO), and others.
• Key Non-small Cell Lung Cancer Pipeline Therapies: INBRX-106, Datopotamab deruxtecan, Bintrafusp alfa, Patritumab deruxtecan, GB 1211, BBP 398, Cofetuzumab pelidotin, Abemaciclib, BNT 116, JMT101, RMC-4630, MGY 825, Adagrasib, JDQ443, TGRX 326, CKD 702, Citarinostat, IBI 110, XZP 3621, BAY 2927088, SRF388, ABBV 514, Gentuximab injection, Befotertinib, Geptanolimab, Naporafenib, IMU-201, Binimetinib, HS 10241, APX005M, Finotonlimab, Encorafenib, Autologous tumour infiltrating lymphocytes, and others.

Dive deep into rich insights for NSCLC emerging therapies and assessment, visit @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late Stage Products (Phase III)
6. Mid Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight

For further information on the NSCLC current pipeline therapeutics, reach out @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Acute Pulmonary Embolism Market: https://www.delveinsight.com/report-store/acute-pulmonary-embolism-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-neoplasms-market
• Carcinoid Tumor Market: https://www.delveinsight.com/report-store/carcinoid-tumor-market
• Cluster Headache Market: https://www.delveinsight.com/report-store/cluster-headache-market
• Condyloma Market: https://www.delveinsight.com/report-store/condyloma-market
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
• Fibrocystic Breast Condition Market: https://www.delveinsight.com/report-store/fibrocystic-breast-condition-market
• Meningioma Market: https://www.delveinsight.com/report-store/meningioma-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Rhino Conjunctivitis Market: https://www.delveinsight.com/report-store/rhino-conjunctivitis-market
• Ventilator Market: https://www.delveinsight.com/report-store/ventilators-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Eczema Market: https://www.delveinsight.com/report-store/eczema-market
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Pharmaceutical Consulting Companies: https://www.delveinsight.com/consulting
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Biotech Consulting: https://www.delveinsight.com/consulting
• Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-cancer-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/osteoarthritis-market
• Pruritus Market: https://www.delveinsight.com/report-store/cholestatic-pruritus-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-small Cell Lung Cancer (NSCLC) Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight here

News-ID: 3486025 • Views:

More Releases from DelveInsight Business Research

Clostridium Difficile Infections Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Novartis AG, Astellas Pharma, Eli Lilly & Company AstraZeneca, Actelion Pharmaceuticals Ltd., Merck & Co. Inc., Ba
Clostridium Difficile Infections Pipeline Drugs Analysis Report, 2024: FDA Appro …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Clostridium Difficile Infections pipeline constitutes 20+ key companies continuously working towards developing 22+ Clostridium Difficile Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Clostridium Difficile Infections Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Clostridium Difficile
Acute Social Anxiety Disorder Market Report 2034: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | GlaxoSmithKline Plc, Viatris Inc, Johnson & Johnson, Novartis AG, Pfizer Inc, AstraZeneca Plc, Aurobindo Pharma Ltd,
Acute Social Anxiety Disorder Market Report 2034: Epidemiology Data, Pipeline Th …
DelveInsight's "Acute Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Acute Social Anxiety Disorder, historical and forecasted epidemiology as well as the Acute Social Anxiety Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Acute Social Anxiety Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click
Acute Bacterial Skin and Skin-Structure Infection Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2024-2034), States DelveInsight | Glenmark Pharma, Melinta Therapeutics, Sandoz Inc, Paratek Pharma, AbbVie Inc., Allergan
Acute Bacterial Skin and Skin-Structure Infection Market is Expected to Expand a …
Acute Bacterial Skin and Skin-Structure Infection Market is expected to grow rapidly with the launch of Basilea Pharmaceutica's Zevtera during the Forecast Period (2024-2034) in the 7MM (United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan). DelveInsight's "Acute Bacterial Skin and Skin-Structure Infection Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Acute Bacterial Skin and Skin-Structure Infection, historical and forecasted epidemiology as
Ulcerated Necrobiosis Lipoidica Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2024-2034), Analyzes DelveInsight | Processa Pharmaceuticals
Ulcerated Necrobiosis Lipoidica Market is Predicted to Exhibit Remarkable Growth …
DelveInsight's "Ulcerated Necrobiosis Lipoidica Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Ulcerated Necrobiosis Lipoidica, historical and forecasted epidemiology as well as the Ulcerated Necrobiosis Lipoidica market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Ulcerated Necrobiosis Lipoidica market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ulcerated Necrobiosis Lipoidica

All 5 Releases


More Releases for Market:

India Tractor Market, Tractor Industry, Market Revenue, Market Growth Analysis, …
How Is India Tractor Market Positioned? In India two-third population is engaged in Agriculture. Tractors form an essential part of this sector. They bring the required efficiency and productivity country needs in its agricultural activity to compete on the international level. The Indian tractor Industry has made preponderant improvement in production capacity and in terms of production volumes. The industry has been successful in indigenization of the technology. The volume growth
Global Optical Interconnects Market, Market Size, Market Shares, Market Growth A …
In integrated circuits, optical interconnects majorly refers to a system of transmitting signals from one fragment of an integrated circuit to another part which is using light. Optical interconnects have been in high demand due to the high latency and power consumption incurred by conventional metal interconnects in conveying electrical signals over long distances, such as in interconnects classed as global interconnects. The International Technology Roadmap for Semiconductors (ITRS) has emphasized
Global Cash Registers Market, Market Growth Analysis, Market Revenue, Market Out …
A cash register or automatic money handling system is a motorized or electric device for registration and calculating dealings at a point of sale. It is typically devoted to a drawer for storage cash and additional valuables. A modern cash register is generally attached to a printer which can print out incomes for record-keeping determinations. The electronics cash register delivers numerous features likes mall price and informal admittance. The rising acceptance of electronic cash register by
Global Organic Food & Beverage Market | Market Size, Market Share, Market Trends …
The term 'organic' has gained much popularity since the last decade, which refers to the process of how certain foods are produced. Organic food is grown without the use of synthetic chemicals, such as human-made pesticides and fertilizers, and does not contain genetically modified organisms (GMOs). According to the recently published report titled, 'Global Organic Food & Beverage Outlook, 2026', by Bonafide Research the organic foods & beverage industry has
Robotic Cardiology Surgery Market Insights Includes Market Share, Market Researc …
Robotic Cardiology Surgery Market Global demand for cardiac surgery robots in 2025 will explode to $XXX billion. This represents an astonishing XX% growth yearly in terms of annual revenue between 2016 and 2025, and a cumulative market total of $7.50 billion during 2017-2025 owing to the substantial increase of robot-based and computer-assisted cardiological surgery procedures for heart disorders. Global Robotic Cardiology Surgery Market 2016-2025: Market Size, Share, Forecast and Strategy is based
Educational Robots Market, Market Segmentation, Market Report, Market Forecast
Global Educational Robots market valued USD 670 Million in 2017 and is likely to grow more than USD 2339.8 Million by 2025 with a compounded annual growth of 16.92% over the forecast period 2018-2025. The market growth is primarily driven by technological enhancements in the field of robotics and increasing use of robots for educational purposes. However, high initial research and development expenses hamper market growth. The main function of